blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2755993

EP2755993 - PSEUDOMONAS EXOTOXIN A WITH LESS IMMUNOGENIC B CELL EPITOPES [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  14.09.2018
Database last updated on 24.08.2024
FormerThe patent has been granted
Status updated on  06.10.2017
FormerGrant of patent is intended
Status updated on  01.09.2017
FormerExamination is in progress
Status updated on  22.08.2017
FormerGrant of patent is intended
Status updated on  20.03.2017
FormerExamination is in progress
Status updated on  23.01.2017
Most recent event   Tooltip17.07.2020Lapse of the patent in a contracting state
New state(s): AL		published on 19.08.2020  [2020/34]
Applicant(s)For all designated states
The U.S.A. as represented by the Secretary, Department of Health and Human Services
National Institutes of Health
Office of Technology Transfer
6011 Executive Boulevard, Suite 325
MSC 7660
Bethesda, MD 20892-7660 / US
[2017/45]
Former [2014/30]For all designated states
The U.S.A. as represented by the Secretary, Department of Health and Human Services
National Institues of Health
Office of Technology Transfer
6011 Executive Boulevard, Suite 325
MSC 7660
Bethesda, MD 20892-7660 / US
Inventor(s)01 / PASTAN, Ira, H.
11710 Beall Mountain Road
Potomac, MD 20854 / US
02 / ONDA, Masanori
320 Lorraine Drive
Rockville, MD 20852 / US
03 / LIU, Wenhai
40 Cornerstone Court
Suite 24
Plantsville, CT 06479 / US
 [2014/30]
Representative(s)Vossius & Partner Patentanwälte Rechtsanwälte mbB
Siebertstrasse 3
81675 München / DE
[2017/45]
Former [2014/30]Vossius & Partner
Siebertstrasse 4
81675 München / DE
Application number, filing date12766780.613.09.2012
[2017/45]
WO2012US55034
Priority number, dateUS201161535668P16.09.2011         Original published format: US 201161535668 P
[2014/30]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2013040141
Date:21.03.2013
Language:EN
[2013/12]
Type: A1 Application with search report 
No.:EP2755993
Date:23.07.2014
Language:EN
The application published by WIPO in one of the EPO official languages on 21.03.2013 takes the place of the publication of the European patent application.
[2014/30]
Type: B1 Patent specification 
No.:EP2755993
Date:08.11.2017
Language:EN
[2017/45]
Search report(s)International search report - published on:EP21.03.2013
ClassificationIPC:C07K14/21, A61K38/16, C12N1/15, C12N1/21, C12N5/10, A61K38/00, C07K16/12, C07K16/28, C07K16/30
[2017/13]
CPC:
A61K38/164 (EP,US); A61K47/6829 (US); A61P35/00 (EP);
C07K14/21 (EP,US); C07K16/1214 (EP,US); C07K16/2851 (US);
C07K16/2896 (EP,US); C07K16/30 (US); A61K38/00 (EP,US);
C07K2317/34 (EP,US); C07K2317/56 (US); C07K2317/622 (EP,US);
C07K2319/01 (US); C07K2319/55 (US) (-)
Former IPC [2014/30]C07K14/21, A61K38/16, C12N1/15, C12N1/21, C12N5/10
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2014/30]
Extension statesBANot yet paid
MENot yet paid
TitleGerman:PSEUDOMONAS EXOTOXIN A MIT WENIGER IMMUNOGENEN B-ZELLEPITOPEN[2014/30]
English:PSEUDOMONAS EXOTOXIN A WITH LESS IMMUNOGENIC B CELL EPITOPES[2014/30]
French:EXOTOXINE A DE PSEUDOMONAS DES ÉPITOPES DE CELLULES B MOINS IMMUNOGÈNES[2014/30]
Entry into regional phase28.02.2014National basic fee paid 
28.02.2014Designation fee(s) paid 
28.02.2014Examination fee paid 
Examination procedure28.02.2014Examination requested  [2014/30]
31.10.2014Amendment by applicant (claims and/or description)
08.05.2015Despatch of a communication from the examining division (Time limit: M04)
18.09.2015Reply to a communication from the examining division
03.02.2016Despatch of a communication from the examining division (Time limit: M04)
13.06.2016Reply to a communication from the examining division
12.09.2016Despatch of a communication from the examining division (Time limit: M04)
18.01.2017Reply to a communication from the examining division
20.03.2017Communication of intention to grant the patent
28.07.2017Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
28.07.2017Fee for grant paid
28.07.2017Fee for publishing/printing paid
25.08.2017Information about intention to grant a patent
25.08.2017Receipt of the translation of the claim(s)
Divisional application(s)EP17195896.0  / EP3301110
The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  08.05.2015
Opposition(s)09.08.2018No opposition filed within time limit [2018/42]
Fees paidRenewal fee
08.09.2014Renewal fee patent year 03
28.09.2015Renewal fee patent year 04
27.09.2016Renewal fee patent year 05
27.09.2017Renewal fee patent year 06
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU13.09.2012
AL08.11.2017
AT08.11.2017
CY08.11.2017
CZ08.11.2017
DK08.11.2017
EE08.11.2017
FI08.11.2017
HR08.11.2017
LT08.11.2017
LV08.11.2017
MC08.11.2017
MK08.11.2017
PT08.11.2017
RO08.11.2017
RS08.11.2017
SE08.11.2017
SI08.11.2017
SK08.11.2017
SM08.11.2017
TR08.11.2017
BG08.02.2018
NO08.02.2018
GR09.02.2018
IS08.03.2018
[2020/34]
Former [2020/31]HU13.09.2012
AT08.11.2017
CY08.11.2017
CZ08.11.2017
DK08.11.2017
EE08.11.2017
FI08.11.2017
HR08.11.2017
LT08.11.2017
LV08.11.2017
MC08.11.2017
MK08.11.2017
PT08.11.2017
RO08.11.2017
RS08.11.2017
SE08.11.2017
SI08.11.2017
SK08.11.2017
SM08.11.2017
TR08.11.2017
BG08.02.2018
NO08.02.2018
GR09.02.2018
IS08.03.2018
Former [2020/28]HU13.09.2012
AT08.11.2017
CY08.11.2017
CZ08.11.2017
DK08.11.2017
EE08.11.2017
FI08.11.2017
HR08.11.2017
LT08.11.2017
LV08.11.2017
MC08.11.2017
PT08.11.2017
RO08.11.2017
RS08.11.2017
SE08.11.2017
SI08.11.2017
SK08.11.2017
SM08.11.2017
TR08.11.2017
BG08.02.2018
NO08.02.2018
GR09.02.2018
IS08.03.2018
Former [2020/16]AT08.11.2017
CY08.11.2017
CZ08.11.2017
DK08.11.2017
EE08.11.2017
FI08.11.2017
HR08.11.2017
LT08.11.2017
LV08.11.2017
MC08.11.2017
RO08.11.2017
RS08.11.2017
SE08.11.2017
SI08.11.2017
SK08.11.2017
SM08.11.2017
TR08.11.2017
BG08.02.2018
NO08.02.2018
GR09.02.2018
IS08.03.2018
Former [2019/24]AT08.11.2017
CY08.11.2017
CZ08.11.2017
DK08.11.2017
EE08.11.2017
FI08.11.2017
HR08.11.2017
LT08.11.2017
LV08.11.2017
MC08.11.2017
RO08.11.2017
RS08.11.2017
SE08.11.2017
SI08.11.2017
SK08.11.2017
SM08.11.2017
BG08.02.2018
NO08.02.2018
GR09.02.2018
IS08.03.2018
Former [2018/52]AT08.11.2017
CY08.11.2017
CZ08.11.2017
DK08.11.2017
EE08.11.2017
FI08.11.2017
HR08.11.2017
LT08.11.2017
LV08.11.2017
RO08.11.2017
RS08.11.2017
SE08.11.2017
SI08.11.2017
SK08.11.2017
SM08.11.2017
BG08.02.2018
NO08.02.2018
GR09.02.2018
IS08.03.2018
Former [2018/40]AT08.11.2017
CY08.11.2017
CZ08.11.2017
DK08.11.2017
EE08.11.2017
FI08.11.2017
HR08.11.2017
LT08.11.2017
LV08.11.2017
RO08.11.2017
RS08.11.2017
SE08.11.2017
SK08.11.2017
SM08.11.2017
BG08.02.2018
NO08.02.2018
GR09.02.2018
IS08.03.2018
Former [2018/37]AT08.11.2017
CY08.11.2017
CZ08.11.2017
DK08.11.2017
EE08.11.2017
FI08.11.2017
HR08.11.2017
LT08.11.2017
LV08.11.2017
RS08.11.2017
SE08.11.2017
SK08.11.2017
SM08.11.2017
BG08.02.2018
NO08.02.2018
GR09.02.2018
IS08.03.2018
Former [2018/35]AT08.11.2017
CY08.11.2017
CZ08.11.2017
DK08.11.2017
EE08.11.2017
FI08.11.2017
HR08.11.2017
LT08.11.2017
LV08.11.2017
RS08.11.2017
SE08.11.2017
SK08.11.2017
BG08.02.2018
NO08.02.2018
GR09.02.2018
IS08.03.2018
Former [2018/24]AT08.11.2017
FI08.11.2017
HR08.11.2017
LT08.11.2017
LV08.11.2017
RS08.11.2017
SE08.11.2017
BG08.02.2018
NO08.02.2018
GR09.02.2018
IS08.03.2018
Former [2018/22]FI08.11.2017
LT08.11.2017
NO08.02.2018
Cited inInternational search[I]WO2007031741  (CAMBRIDGE ANTIBODY TECH [GB], et al) [I] 1-43 * Whole document, especially tables 1 and 3 *;
 [AD]WO2009032954  (US GOV HEALTH & HUMAN SERV [US], et al) [AD] 1-43 * Whole document, especially the claims *;
 [X]  - "Target specific chimeric toxin associated protein.", Geneseq, (20020813), Database accession no. AAU96810, URL: EBI, XP002688095 [X] 1,2,4-6,22,27,36,37 * the whole document *
 [I]  - ONDA MASANORI ET AL, "Characterization of the B cell epitopes associated with a truncated form of Pseudomonas exotoxin (PE38) used to make immunotoxins for the treatment of cancer patients", THE JOURNAL OF IMMUNOLOGY, THE AMERICAN ASSOCIATION OF IMMUNOLOGISTS, US, (20061201), vol. 177, no. 12, ISSN 0022-1767, pages 8822 - 8834, XP002420637 [I] 1-43 * Whole document, especially page 8827 left column *
 [I]  - M. ONDA ET AL, "Recombinant immunotoxin against B-cell malignancies with no immunogenicity in mice by removal of B-cell epitopes", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, (20110405), vol. 108, no. 14, doi:10.1073/pnas.1102746108, ISSN 0027-8424, pages 5742 - 5747, XP055036968 [I] 1-43 * Whole document, especially figure 2 *

DOI:   http://dx.doi.org/10.1073/pnas.1102746108
 [A]  - ROSCOE D M ET AL, "Identification of epitopes on a mutant form of Pseudomonas exotoxin using serum from humans treated with Pseudomonas exotoxin containing immunotoxins", EUROPEAN JOURNAL OF IMMUNOLOGY, WILEY - V C H VERLAG GMBH & CO. KGAA, DE, (19970601), vol. 27, no. 6, doi:10.1002/EJI.1830270624, ISSN 0014-2980, pages 1459 - 1468, XP000857609 [A] 1-43 * Whole document, especially Figure 4. *

DOI:   http://dx.doi.org/10.1002/eji.1830270624
 [A]  - NAGATA S ET AL, "Removal of B cell epitopes as a practical approach for reducing the immunogenicity of foreign protein-based therapeutics", ADVANCED DRUG DELIVERY REVIEWS, ELSEVIER BV, AMSTERDAM, NL, vol. 61, no. 11, doi:10.1016/J.ADDR.2009.07.014, ISSN 0169-409X, (20090930), pages 977 - 985, (20090811), XP026666157 [A] 1-43 * the whole document *

DOI:   http://dx.doi.org/10.1016/j.addr.2009.07.014
by applicantUS4450150
 EP0173494
 WO8702671
 GB2188638
 US4816567
 US4892827
 EP0404097
 US5087616
 WO9311161
 US5225539
 US5242824
 EP0239400
 US5449752
 US5512658
 US5545806
 US5569825
 US5585089
 US5602095
 US5608039
 US5639641
 US5693761
 US5714352
 US5747654
 US5821238
 WO9845322
 US5846535
 US5854044
 US5859205
 US5888773
 US5889157
 WO9951643
 US5981726
 US5990296
 US6265150
 US2002197266
 WO03027135
 US6558672
 US7081518
 WO2007016150
 US2007189962
 US7355012
 US7368110
 US7470775
 WO2009032954
 US7521054
 WO2011032022
    - SIEGALL ET AL., J. BIOL. CHERN., (1989), vol. 264, pages 14256 - 14261
    - PAI ET AL., PROC. NAT 'L ACAD. SCI. USA, (1991), vol. 88, pages 3358 - 62
    - KONDO ET AL., BIOL. CHEM., (1988), vol. 263, pages 9470 - 9475
    - WANG J. ET AL., CELL, (1987), vol. 48, pages 129 - 136
    - PASTAN ET AL., BIOCHIM. BIOPHYS. ACIA, (1997), vol. 1333, pages CL - C6
    - DUCKERT ET AL., PROTEIN ENGINEERING, DESIGN & SELECTION, (2004), vol. 17, no. 1, pages 107 - 112
    - WADWA ET AL., J. DRUG TARGETING, (1995), vol. 3, page 111
    - JONES ET AL., NATURE, (1986), vol. 321, page 522
    - VERHOEYEN ET AL., SCIENCE, (1988), vol. 239, page 1534
    - RIECHMANN ET AL., NATURE, (1988), vol. 332, page 323
    - WINTER; MILSTEIN, NATURE, (1991), vol. 349, page 293
    - WESOLOWSKI, MED MICROBIOL IMMUNOL., (2009), vol. 198, no. 3, pages 157 - 74
    - SAERENS ET AL., CURR. OPIN. PHARMACOL., (2008), vol. 8, no. 5, pages 6 00 - 8
    - HANNSEN; DE HAARD, APPL. MICROBIOL. BIOTECHNOL., (2007), vol. 77, no. 1, pages 13 - 22
    - ARNDT ET AL., J. MOL. BIOL., (2001), vol. 312, pages 221 - 228
    - HOLLINGER ET AL., PROC. NATL. ACAD. SCI. USA, (1993), vol. 90, pages 6444 - 6448
    - HOLT ET AL., TRENDS BIOTECH, (2003), vol. 21, no. 11, pages 484 - 490
    - GHAHROUDI, FEBS LETT., (1997), vol. 414, pages 521 - 526
    - LAUWEREYS ET AL., EMBO J, (1998), vol. 17, pages 3512 - 3520
    - REITER ET AL., J. MOL. BIOL., (1999), vol. 290, pages 685 - 698
    - DAVIES; RIECHMANN, BIOTECHNOLOGY, (2001), vol. 13, pages 475 - 479
    - KOHLER; MILSTEIN, EUR. J. IMMUNOL., (1976), vol. 5, pages 511 - 519
    - HASKARD; ARCHER, J. IMMUNOL. METHODS, (1984), vol. 74, no. 2, pages 361 - 67
    - RODER ET AL., METHODS ENZYMOL., (1986), vol. 121, pages 140 - 67
    - HUSE ET AL., SCIENCE, (1989), vol. 246, pages 1275 - 81
    - PEDERSEN ET AL., J. MOL. BIO/., (1994), vol. 235, pages 959 - 973
    - MUFSON ET AL., FRONT. BIOSCI., (2006), vol. 11, pages 337 - 43
    - FRANKEL ET AL., CLIN. CANCER RES., (2000), vol. 6, pages 326 - 334
    - KREITMAN ET AL., AAPS JOURNAL, (2006), vol. 8, no. 3, pages E532 - E551
    - BANKER AND CHALMERS, Pharmaceutics and Pharmacy Practice, J.B. LIPPINCOTT COMPANY, (1982), pages 238 - 250
    - ASHP Handbook on Injectable Drugs, 4th ed.,, (1986), pages 622 - 630
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.